ANI Pharmaceuticals, Inc.
ANIP
$64.95
-$0.48-0.73%
| Weiss Ratings | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | C+ | |||
| Rating Factors | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.73 | |||
| Price History | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -3.44% | |||
| 30-Day Total Return | -2.34% | |||
| 60-Day Total Return | 18.19% | |||
| 90-Day Total Return | 25.16% | |||
| Year to Date Total Return | 12.92% | |||
| 1-Year Total Return | 66.83% | |||
| 2-Year Total Return | 102.57% | |||
| 3-Year Total Return | 95.99% | |||
| 5-Year Total Return | -7.27% | |||
| 52-Week High % Change | -7.33% | |||
| 52-Week Low % Change | 77.40% | |||
| Price | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $70.81 | |||
| 52-Week Low Price | $36.99 | |||
| 52-Week Low Price (Date) | Apr 26, 2023 | |||
| 52-Week High Price (Date) | Mar 25, 2024 | |||
| Valuation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.37B | |||
| Enterprise Value | 1.47B | |||
| Price/Earnings (TTM) | 78.42 | |||
| Earnings Per Share (TTM) | 0.84 | |||
| Earnings Per Share Growth | -127.29% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.59 | |||
| Price/Book (Q) | 2.89 | |||
| Enterprise Value/Revenue (TTM) | 3.02 | |||
| Price | $64.58 | |||
| Enterprise Value/EBITDA (TTM) | 13.46 | |||
| Enterprise Value/EBIT | 29.72 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 19.22M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 8.65% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 218 634 3500 | |||
| Address | 210 Main Street West Baudette, MN 56623 | |||
| Website | www.anipharmaceuticals.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 10.17% | |||
| Profit Margin | 3.85% | |||
| Management Effectiveness | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 3.72% | |||
| Return on Equity | 4.72% | |||
| Income Statement | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 486.82M | |||
| Total Revenue (TTM) | 486.82M | |||
| Revenue Per Share | $25.33 | |||
| Gross Profit (TTM) | 305.30M | |||
| EBITDA (TTM) | 109.32M | |||
| EBIT (TTM) | 49.53M | |||
| Net Income (TTM) | 18.78M | |||
| Net Income Avl. to Common (TTM) | 17.15M | |||
| Total Revenue Growth (Q YOY) | 39.71% | |||
| Earnings Growth (Q YOY) | 127.22% | |||
| EPS Diluted (TTM) | 0.84 | |||
| EPS Diluted Growth (Q YOY) | 112.47% | |||
| Balance Sheet | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 221.12M | |||
| Cash Per Share (Q) | $11.51 | |||
| Total Current Assets (Q) | 519.82M | |||
| Total Preferred Equity (Q) | 24.85 | |||
| Total Equity (Q) | 457.60M | |||
| Current Ratio (Q) | 3.573 | |||
| Book Value Per Share (Q) | $22.64 | |||
| Total Assets (Q) | 904.42M | |||
| Total Current Liabilities (Q) | 145.48M | |||
| Total Debt (Q) | 291.34M | |||
| Total Liabilities (Q) | 446.82M | |||
| Total Common Equity (Q) | 432.75M | |||
| Cash Flow | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -18.51M | |||
| Cash from Financing (TTM) | 67.44M | |||
| Net Change in Cash (TTM) | 167.89M | |||
| Levered Free Cash Flow (TTM) | 113.47M | |||
| Cash from Operations (TTM) | 118.96M | |||
